In 2022, the Destiny-Lung01 trial showed lasting anticancer activity in patients with non-small-cell lung cancer (NSCLC) refractory to standard treatments.(16) After this clinical advancement, scientists explored the possibility of T-DXd being active against other types of unresectable and/or metastatic solid cancers with HER2 mutations, leading to the development of the Destiny-Pan Tumor01 trial. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.